Sarepta Therapeutics Inc. [NASDAQ: SRPT] slipped around -4.52 points on Wednesday, while shares priced at $76.92 at the close of the session, down -5.55%. The company report on May 18, 2021 that Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material.
Results from the first 11 participants enrolled in Study 9001-103 ENDEAVOR showed robust transduction, delivering mean vector genome copies of 3.87 per nucleus.
Treated patients achieved mean micro-dystrophin expression levels of 55.4% of normal as measured by western blot.
Sarepta Therapeutics Inc. stock is now -54.88% down from its year-to-date (YTD) trading value. SRPT Stock saw the intraday high of $79.2467 and lowest of $75.14 per share. The company’s 52-week high price is 181.83, which means current price is +13.65% above from all time high which was touched on 01/04/21.
Compared to the average trading volume of 1.18M shares, SRPT reached a trading volume of 1964573 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sarepta Therapeutics Inc. [SRPT]?
Credit Suisse have made an estimate for Sarepta Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 26, 2021. While these analysts kept the previous recommendation, Citigroup dropped their target price from $215 to $108. The new note on the price target was released on January 12, 2021, representing the official price target for Sarepta Therapeutics Inc. stock.
The Average True Range (ATR) for Sarepta Therapeutics Inc. is set at 3.96, with the Price to Sales ratio for SRPT stock in the period of the last 12 months amounting to 10.20. The Price to Book ratio for the last quarter was 11.41, with the Price to Cash per share for the same quarter was set at 22.85.
How has SRPT stock performed recently?
Sarepta Therapeutics Inc. [SRPT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.10. With this latest performance, SRPT shares gained by 7.88% in over the last four-week period, additionally sinking by -44.94% over the last 6 months – not to mention a drop of -47.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRPT stock in for the last two-week period is set at 53.89, with the RSI for the last a single of trading hit 55.59, and the three-weeks RSI is set at 51.25 for Sarepta Therapeutics Inc. [SRPT]. The present Moving Average for the last 50 days of trading for this stock 75.29, while it was recorded at 76.41 for the last single week of trading, and 117.81 for the last 200 days.
Sarepta Therapeutics Inc. [SRPT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sarepta Therapeutics Inc. [SRPT] shares currently have an operating margin of -104.44 and a Gross Margin at +83.28. Sarepta Therapeutics Inc.’s Net Margin is presently recorded at -102.60.
Return on Total Capital for SRPT is now -33.07, given the latest momentum, and Return on Invested Capital for the company is -32.77. Return on Equity for this stock declined to -70.15, with Return on Assets sitting at -23.05. When it comes to the capital structure of this company, Sarepta Therapeutics Inc. [SRPT] has a Total Debt to Total Equity ratio set at 143.59. Additionally, SRPT Total Debt to Total Capital is recorded at 58.95, with Total Debt to Total Assets ending up at 36.65. Long-Term Debt to Equity for the company is recorded at 140.84, with the Long-Term Debt to Total Capital now at 57.82.
Reflecting on the efficiency of the workforce at the company, Sarepta Therapeutics Inc. [SRPT] managed to generate an average of -$639,871 per employee. Receivables Turnover for the company is 4.65 with a Total Asset Turnover recorded at a value of 0.22.Sarepta Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.60 and a Current Ratio set at 6.20.
Earnings analysis for Sarepta Therapeutics Inc. [SRPT]
With the latest financial reports released by the company, Sarepta Therapeutics Inc. posted -1.93/share EPS, while the average EPS was predicted by analysts to be reported at -1.68/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -14.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRPT.
Insider trade positions for Sarepta Therapeutics Inc. [SRPT]
There are presently around $5,069 million, or 87.30% of SRPT stock, in the hands of institutional investors. The top three institutional holders of SRPT stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 8,026,903, which is approximately 3.75% of the company’s market cap and around 4.70% of the total institutional ownership; VANGUARD GROUP INC, holding 7,366,100 shares of the stock with an approximate value of $566.6 million in SRPT stocks shares; and JANUS HENDERSON GROUP PLC, currently with $474.74 million in SRPT stock with ownership of nearly 59.246% of the company’s market capitalization.
Positions in Sarepta Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 202 institutional holders increased their position in Sarepta Therapeutics Inc. [NASDAQ:SRPT] by around 12,664,887 shares. Additionally, 263 investors decreased positions by around 16,935,048 shares, while 45 investors held positions by with 36,294,150 shares. The mentioned changes placed institutional holdings at 65,894,085 shares, according to the latest SEC report filing. SRPT stock had 66 new institutional investments in for a total of 1,685,935 shares, while 139 institutional investors sold positions of 4,241,893 shares during the same period.